好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Association of the Central Vein Sign and “Paramagnetic Rims” with Cognitive Impairment in Radiologically Isolated Syndrome
Multiple Sclerosis
S24 - Pregnancy, Pediatric MS, and Early MS (4:42 PM-4:54 PM)
007

To assess relationships between cognitive impairment and the central vein sign, paramagnetic rim sign, and brain atrophy in radiologically isloated syndrome

Radiologically isolated syndrome(RIS) describes asymptomatic individuals with incidental MRI abnormalities highly suggestive of multiple sclerosis(MS). Using susceptibility-weighted imaging, we previously showed that a significant proportion of white matter lesions(WML) in RIS have visible CVS and demonstrate an increase in magnetic susceptibility along the lesion rim(PRS), which may represent chronic, smoldering inflammation.  

27 RIS subjects underwent 3.0T-MRI and cognitive assessment using the minimal assessment of cognitive function in MS(MACFIMS)battery. The CVS and PRS were assessed in WMLs on T2*-magnitude and phase images. Brain segmentation was performed with Multi-Atlas CRUISE to assess brain atrophy. Spearman’s coefficient and multivariable linear regression evaluated relationships between CI and MRI measures.

37%of RIS had global CI and 93%had a proportion of CVS+WML that was>40%. 58%of RIS demonstrated PRS+WML, and the mean proportion of PRS+WML was 12%. There were significant correlations between individual cognitive tests and proportions of CVS+WML and PRS+WML, with the strongest correlations observed with the California Verbal Learning Test-II(CVLT-II) and CVS+WML(ρ=-0.54,p<0.01) and PRS+WML(ρ=-0.44,p=0.02). When relationships between CI, CVS,and PRS were assessed in multivariable models controlling for brain volume:CVS+WML(p=0.02) and PRS+WML(p=0.05) demonstrated relationships with the CVLT-II(p=0.02;p=0.05, respectively) and the Paced Auditory Serial Addition Test(p<0.01;p=0.02,respectively).

CI is common in RIS and demonstrates significant relationships with CVS+WML and PRS+WML,independent of brain atrophy. The CVS and PRS are thought to reflect perivenular demyelination and chronic inflammation, respectively. These findings suggest that perivenular demyelination and chronic, smoldering inflammation in WML are relevant to CI in RIS, and raise the possibility that CI may be useful to identify those at higher risk of conversion to MS. Prospective follow-up of this cohort will give insight into the predictive value of CI, CVS, and PRS in the clinical management of RIS.

Authors/Disclosures
Mariana Espinosa-Polanco
PRESENTER
No disclosure on file
No disclosure on file
Anthony Feinstein, MD (Sunnybrook Health Sciences Centre) Anthony Feinstein, MD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis, Biogen, Roche and Sanofi-Genzyme. The institution of Anthony Feinstein, MD has received research support from Multiple Sclerosis Society of Canada. Anthony Feinstein, MD has received publishing royalties from a publication relating to health care.
No disclosure on file
Martina Absinta, MD Dr. Absinta has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Absinta has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abata Therapeutics. The institution of Dr. Absinta has received research support from International MS Alliance. The institution of Dr. Absinta has received research support from FRRB Early Career Award. The institution of Dr. Absinta has received research support from Cariplo Foundation.
Melanie Guenette No disclosure on file
No disclosure on file
Daniel Reich, MD, PhD (National Institutes of Health, Neuroimmunology Branch, NINDS) Dr. Reich has received research support from NIH. The institution of Dr. Reich has received research support from Adelson Medical Research Foundation. The institution of Dr. Reich has received research support from Sanofi. The institution of Dr. Reich has received research support from Abata Therapeutics. The institution of Dr. Reich has received research support from National Multiple Sclerosis Society. Dr. Reich has received intellectual property interests from a discovery or technology relating to health care. Dr. Reich has received personal compensation in the range of $5,000-$9,999 for serving as a CME Faculty with PeerView. Dr. Reich has received personal compensation in the range of $5,000-$9,999 for serving as a CME Faculty with Integrity. Dr. Reich has received personal compensation in the range of $500-$4,999 for serving as a CME Faculty with Letters and Sciences. Dr. Reich has received personal compensation in the range of $500-$4,999 for serving as a CME Faculty with Academic CME. Dr. Reich has a non-compensated relationship as a Advisor with Sanofi that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Board of Directors with ACTRIMS that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Abata Therapeutics that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with University of Basel RC2NB that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Multiple Sclerosis Society of Canada that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Tuscan Doctorate in Neuroscience that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Editorial Board with Multiple Sclerosis Journal that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Biohaven that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Sana that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Merck KGaA EMD Serono that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Bristol-Meyers Squibb that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with ChemoCentryx that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator, Advisor with Hyperfine that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Imaginab that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Perceptive that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Annexon that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator, Advisor with Philips that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Siemens that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Novartis that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Calico Life Sciences that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Cognito Therapeutics that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Sudo that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Allumis that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with BioCentury that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Regeneron that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Eli Lilly that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with SetPoint that is relevant to AAN interests or activities.
No disclosure on file